FOLH1 and prostate cancer: The alpha emitter 223Radium-dichloride (223Ra) and the beta emitter 177Lutetium (177Lu) targeting the prostate-specific membrane antigen (PSMA) are sequentially used for therapy of advanced bone-metastatic castration-resistant prostate cancer.